Case 3: Atezolizumab/Nab-Paclitaxel for Triple Negative Breast Cancer
Watch
Case 2: Choosing a CDK4/6 Inhibitor in ER+ Breast Cancer
Case 1: Approach to Early Stage, HER2+ Breast Cancer
Case 4: Chemotherapy or PARP inhibitors for BRCA+ TNBC
Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer
Case 4: OlympiAD Trial for BRCA+ Metastatic TNBC
Case 4: BRCA+ Metastatic Breast Cancer
Case 3: Treatment After Progression in Triple-Negative Breast Cancer
Case 3: Managing Immune-Related Adverse Effects in TNBC
Case 3: PD-L1 Testing Used in Triple-Negative Breast Cancer
Case 3: The Use of Combination Therapy in Triple-Negative Breast Cancer
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
Case 3: Metastatic Triple-Negative Breast Cancer
Case 2: CDK4/6 Inhibitor Recommendations in ER+ Breast Cancer
Case 2: Defining Strongly Versus Less Strongly ER+ Breast Cancer
Case 2: Treatment Recommendations for ER+ Breast Cancer
Case 2: CDK4/6 Inhibitors in ER+ Breast Cancer
Case 2: ER+ Breast Cancer
Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
Case 1: Treatment for Early-Stage HER2+ Breast Cancer
Case 1: Clinical Trials in Early-Stage HER2+ Breast Cancer
Case 1: When to Use FISH Testing in Breast Cancer
Case 1: Guidelines for HER2 Testing in Breast Cancer
Case 1: Decision Making in Early Stage HER2+ Breast Cancer
Case 1: Early-Stage HER2+ Breast Cancer
Breast Cancer
Experts in breast oncology review 4 clinical cases and discuss individualized treatment approaches for each patient.
Evaluating Safety Concerns in Patients With Hairy Cell Leukemia
Kerry Rogers, MD, discusses an important unmet need in patients with hairy cell leukemia.
ECHELON-1 Trial Shows Continued Efficacy Over Time in Hodgkin Lymphoma
Tatyana Feldman, MD, discusses the design and efficacy of the ECHELON-1 trial investigating brentuximab vedotin with chemotherapy in patients with stage III or IV Hodgkin lymphoma after a 3-year update.
Follow-Up Shows Venetoclax Plus Rituximab has Long-Term Efficacy in CLL
Alexey V. Danilov, MD, PhD, discusses a treatment regimen of venetoclax plus rituximab used for patients with chronic lymphocytic leukemia the 2019 American Society of Hematology Annual Meeting.
Rationale for Evaluating STING Agonists in Head and Neck Cancer
Robert L. Ferris, MD, PhD, discusses the rationale for evaluating STING agonists as treatment for patients with head and neck cancers.